Abstract-Dopamine is an important modulator of blood pressure, in part, by regulating vascular resistance. To test the hypothesis that D 1 and D 3 receptors interact in vascular smooth muscle cells, we studied A10 cells, a rat aortic smooth muscle cell line, and rat mesenteric arteries that express both dopamine receptor subtypes. Both D 1 and D 3 receptors are expressed in vascular smooth muscle cells, and the activation of the D 1 receptor relaxes blood vessels and decreases blood pressure. 5, 6 However, the effect of D 3 receptors on resistance vessels is not clear. A low intravenous dose of R(ϩ)-7-hydroxydipropyl-aminotetralin (7-OH-DPAT), a D 2 -like agonist with a 50-fold selectivity for the D 3 over the D 2 receptor, constricts postglomerular arterioles without affecting systemic blood pressure. 4 A higher dose, however, decreases blood pressure. 4 To test the hypothesis that D 1 and D 3 receptors interact in vascular smooth muscle cells, we studied the effect of fenoldopam, a D 1 -like receptor agonist, on D 1 and D 3 receptor expressions in rat thoracic aorta-derived smooth muscle cell line (A10). 7 We also studied the effect of D 1 and D 3 receptor agonists on the wall tension of rat mesenteric arterial rings.
D
opamine, a well known neurotransmitter in the central nervous system, has recently been characterized as an important modulator of blood pressure, sodium balance, and renal and adrenal function and is relevant to the pathogenesis and/or maintenance of hypertension. [1] [2] [3] [4] Dopamine receptors are classified into 2 families: the D 1 -like receptor subfamily includes the D 1 and the D 5 receptor, while the D 2 , D 3 , and D 4 receptors belong to the D 2 -like subfamily. Whereas the D 1 -like receptors couple to the stimulatory G protein, G␣ S , and thus activate adenylyl cyclase, all of the D 2 -like receptors couple to the inhibitory G protein, G␣ i /G␣ O , and inhibit adenylyl cyclase and calcium channels and modulate potassium channels. [1] [2] [3] [4] Both D 1 and D 3 receptors are expressed in vascular smooth muscle cells, and the activation of the D 1 receptor relaxes blood vessels and decreases blood pressure. 5, 6 However, the effect of D 3 receptors on resistance vessels is not clear. A low intravenous dose of R(ϩ)-7-hydroxydipropyl-aminotetralin (7-OH-DPAT), a D 2 -like agonist with a 50-fold selectivity for the D 3 over the D 2 receptor, constricts postglomerular arterioles without affecting systemic blood pressure. 4 A higher dose, however, decreases blood pressure. 4 To test the hypothesis that D 1 and D 3 receptors interact in vascular smooth muscle cells, we studied the effect of fenoldopam, a D 1 -like receptor agonist, on D 1 and D 3 receptor expressions in rat thoracic aorta-derived smooth muscle cell line (A10). 7 We also studied the effect of D 1 and D 3 receptor agonists on the wall tension of rat mesenteric arterial rings.
Methods

Cell Culture and Sample Preparation
Embryonic thoracic aortic smooth muscle cells 7, 8 (passage 10 to 20) from normotensive Berlin-Druckrey IX (A10; CRL 1476, ATCC) were cultured at 37°C in 95% air/5% CO 2 atmosphere in Dulbecco modified eagle medium.
A10 cells (80% confluence) and mesenteric arteries from sodium pentobarbital-anesthetized Wistar-Kyoto (WKY) rats (Taconic, Germantown, NY) were homogenized in ice-cold lysis buffer (5 mL/g tissue) (20 mmol/L Tris-HCl, pH 7.4; 2 mmol/L EDTA, pH 8.0; 2 mmol/L EGTA; 100 mmol/L NaCl; 10 g/mL leupeptin; 10 g/mL aprotinin; 2 mmol/L phenylmethylsulfonyl fluoride; 1% NP-40), sonicated, kept on ice for 1 hour, and centrifuged at 16 000g for 30 minutes. All samples were stored at Ϫ70°C until use. All experiments were approved by the Georgetown University Animal Use and Care Committee.
Immunoblotting
The antibodies are polyclonal, purified, and antipeptides. The rat D 1 receptor immunizing peptide (299-GSEETQPFC-307) (Research Genetics) 9 -12 and the rat D 3 receptor immunizing peptide (r288-QPP SPG QTH GGL KRY YSI C-306) are located on the third extracellular loop of their corresponding receptors. 13, 14 The specificity of these antibodies has been reported. 9 -14 M) for 24 hours, as described. 9, 14 Equal amounts of cell lysates (200 g protein/mL supernatant) were incubated with affinity-purified anti-D 1 receptor antibodies (2 L/mL) for 1 hour and protein-G agarose at 4°C for 12 hours. The immunoprecipitates were suspended in sample buffer (2X sample buffer: 100% glycerol 2.0 mL; 0.5 mmol/L Tris-HCl 2.5 mL, pH 6.8; 10% SDS 4 mL [final concentrationϭ0.14 mmol/L]; 2 mg/mL bromophenol blue 0.5 mL; 2-mercaptoethanol 0.5 mL, added dH 2 O until total volume 10 mL), boiled for 10 minutes, and subjected to immunoblotting with the D 3 receptor antibody. To determine the specificity of the bands found on the immunoblots, preimmune serum of D 1 receptor antibody (negative control) and D 3 receptor antibodies (positive control) were used as the immunoprecipitates instead of the D 1 receptor antibodies.
Immunohistochemistry
The rat mesenteric artery, cleared of blood with ice-cold oxygenated saline and kept in Histochoice (Amresco, Solon, Ohio) for 1 to 2 days at 4°C, were sectioned (4 m), embedded in paraffin, and mounted on slides. 17 The tissue was deparaffinized and rehydrated by successive incubations in xylene, 100% ethanol, 95% ethanol, 75% ethanol, and phosphate-buffered saline. The tissue was then briefly treated with 0.1% Triton X-100, 10 mmol/L sodium citrate (pH 6.0), and blocked sequentially with 5% goat serum in phosphate-buffered saline overnight at 4°C. The tissue sections were incubated with anti-D 3 receptor antibody (1:200) at room temperature for 1.5 hours. After staining with Vector VIP substrate kit, the slides were permanently mounted. The primary antibodies, previously incubated with the immunizing peptides (1:10) at 4°C for 12 hours, were used as controls.
Mesenteric Artery Study
A portion of intestine and mesentery removed from male WKY rats (300 to 350 g, nϭ12) anesthetized with sodium pentobarbital (50 mg/kg) was kept in ice-cold physiological salt solution (PSS). Four segments of third-generation resistance vessels were dissected under an operating microscope (Olympus, SZ40) and mounted as ring preparations on four 40-m stainless-steel wires in an isometric Mulvany-Halpern small-vessel myograph (model M610M; J.P. Trading, Science Park, Aarhus, Denmark). 18 One wire was attached to a force transducer and the other to a micrometer. 18, 19 This arrangement enabled the wall tension to be measured at a predetermined internal circumference. Both the dissection and mounting of the vessels were performed in ice-cold (4°C) PSS.
After mounting, the arterial ring was equilibrated in PSS for 1 hour at 37°C at a wall tension of 0.1 mN/mm. Based on preliminary data from Ͼ100 vessels, we confirmed that a normalized circumference (L 0 )ϭ0.9 L 100 results in maximal active force development. The vessels were studied at L 0 in all subsequent protocols.
After testing the constrictor effects of high-potassium PSS (KPSS, 125 mmol/L) or PSS containing 10 Ϫ5 M norepinephrine, the vessels were rinsed 3 times with fresh PSS and allowed to recover to baseline for 15 minutes. Maximal contraction of the vessel was then achieved with 10 Ϫ5 M norepinephrine and KPSS. After reaching a plateau, relaxation was induced with 10 Ϫ5 M of acetylcholine to test endothelium-dependent relaxation. Ligand-induced relaxation was assessed by cumulative addition of drugs to the rings, which were submaximally (50% to 80%) preconstricted with norepinephrine or KPSS.
To . 20, 24 To investigate the mechanisms of ligand-mediated vasorelaxation, studies were performed in vessels preincubated for 30 minutes with nifedipine (Sigma) 25 or apamin (Sigma) (10 Ϫ6 M; a small conductance calcium-activated K ϩ channel blocker) 26 and charybdotoxin (Sigma) (10 Ϫ6 M; a large conductance calcium-activated K ϩ channel blocker). 26 To determine the endothelium dependence of any D 1 or D 3 receptor agonist-induced relaxation, vessels with or without endothelium were studied. The endothelium was removed by pulling a hair along the vessels; successful denudement of the endothelium was confirmed by an absence of relaxation by acetylcholine. 27 To test any interaction between D 1 or D 3 receptors, PD128907 (10 Ϫ10 to 10 Ϫ3 M) studies were performed in vessels preincubated for 30 minutes with fenoldopam (10 Ϫ6 M). To confirm the D 3 receptormediated vasorelaxation, we used 2 other D 3 receptor ligands, 7-OH-DPAT 20, 22 (agonist), and (ϩ)-UH232 20,24 (antagonist).
Statistical Analysis
The data are expressed as meanϮSEM. Comparison within groups was made by repeated measures ANOVA (or paired t test when only 2 groups were compared), and comparison among groups (or t test when only 2 groups were compared) was made by factorial ANOVA with Duncan test. Corresponding periods between 2 different groups were analyzed by independent t test. Fenoldopam and PD128907 sensitivity are expressed as pED 50 , which is the (Ϫlog) concentration of the drug required to produce 50% of the maximum response. Relaxation responses to fenoldopam and PD128907 are expressed as a percentage decrease from the maximum contractile response. A value of PϽ0.05 was considered significant.
Results
Specificity of Receptor Antibodies
Specific D 3 receptor (Ϸ45 kDa) bands were found in A10 cells ( Figure 1, lane 2) , because they were no longer visible when the antibodies were pre-adsorbed by the immunizing peptide. The immunoblotting patterns of the D 3 and D 1 receptors were similar to those in our previous reports. 9, 11, 13, 14, 17 
D 1 Receptors Increase D 3 Receptor Protein Expression in A10 Cells
The D 1 -like receptor agonist, fenoldopam, increased D 3 receptor protein in a concentration-dependent and timedependent manner. The stimulatory effect at 24 hours was evident at 10 Ϫ9 M (Figure 2A ). The stimulatory effect of fenoldopam (10 Ϫ7 M) was noted at 16 hours and maintained for at least 24 hours ( Figure 2B ).
The specificity of fenoldopam as a D 1 -like receptor agonist was determined by studying the effect of a D 1 -like receptor antagonist, SCH23390. Consistent with the data shown in Figure 2A and 2B, fenoldopam (10 Ϫ7 M/24 h) increased D 3 receptor protein (controlϭ21Ϯ1 DU, fenoldopamϭ33Ϯ2 DU; nϭ10; PϽ0.05). SCH23390 (10 Ϫ7 M) by itself had no effect on D 3 receptor protein (23Ϯ2 DU) but reversed the stimulatory effect of fenoldopam on D 3 receptor protein expression (fenoldopamϩSCH23390ϭ23Ϯ2 DU; nϭ10) ( Figure 2C ). To determine whether there is mutual receptor interaction, A10 cells were treated with PD128907 (10 Ϫ10 
D 3 Receptor Exists in Rat Mesenteric Artery
We also determined whether the D 3 receptor is expressed in rat mesenteric arteries. Consistent with the results in A10 cells, the D 3 receptor immunoblots of mesenteric artery homogenates also showed a 45-kDa band (Figure 1, lane 1) . Immunohistochemistry showed D 3 receptors in the tunica media and intima ( Figure 5 ). Both the immunoblotting and immunohistochemistry results were specific, because the immunoblot (Figure 1 
Zeng et al D 1 Receptor Regulation of D 3 Receptors
(fenoldopam) and D 3 receptor agonists (PD128907 and 7-OH-DPAT) had no vasoconstrictor effect but relaxed arterial rings preconstricted with KPSS in a dose-dependent manner; the vasorelaxant effects were evident at 10 Ϫ6 M (fenoldopam: Emax [maximum relaxation rate]ϭ83%Ϯ11%, pED 50 ϭ5Ϯ0.2, nϭ12; PD128907: Emaxϭ76%Ϯ6%, pED 50 ϭ5Ϯ0.1, nϭ12; 7-OH-DPAT: Emaxϭ87%Ϯ2%, pED 50 ϭ7Ϯ0.2, nϭ4) ( Figure 6A ). However, the ability of fenoldopam or PD128907 to relax vessels preconstricted with 10 Ϫ5 M norepinephrine was markedly impaired when compared with vessels preconstricted with KPSS (pED 50 
01).
The D 1 and D 3 receptor agonist vasorelaxant effects were endothelium-independent, because the vasorelaxant effects of fenoldopam and PD128907 were not affected by the presence or absence of the endothelium (10 Ϫ6 M PD128907: with endotheliumϭ25%Ϯ4%; without endotheliumϭ24%Ϯ6%; 10 Ϫ6 M fenoldopam: with endotheliumϭ29%Ϯ5%, without endotheliumϭ26%Ϯ6%, PϾ0.05, nϭ12) ( Figure 6B and C) .
Effect of Antagonists
The vasorelaxant effects of D 1 and D 3 receptors were specific, because the D 1 -like receptor antagonist, SCH23390 (2%Ϯ1%), D 3 receptor antagonists, U99194A (2%Ϯ0.02%) and (ϩ)-UH232 (9%Ϯ3%), did not have any effect by themselves but blocked the vasorelaxant effects of their respective agonists: fenoldopam (10 Ϫ6 M) (fenoldopamϭ29%Ϯ5%, fenoldopam؉SCH23390ϭ3%Ϯ3%, PϽ0.01, nϭ12); PD128907 (10 Ϫ6 M) (PD128907ϭ24%Ϯ6%, PD128907؉U99194Aϭ4%Ϯ2%, PϽ0.01, nϭ12), 7-OH DPAT (7-OH-DPATϭ90%Ϯ2%, 7-OH-DPAT؉U99194Aϭ11%Ϯ4%, PϽ0.01, nϭ4) ( Figure 6B, C, and D) .
Effect of combined D 1 and D 3 receptor stimulation is described herein. PD128907-induced vasorelaxation was increased in vessel preincubated with fenoldopam compared with vehicle (% relaxation at 10 Ϫ6 M: fenoldopamϭ40%Ϯ5%, vehicleϭ24%Ϯ6%, nϭ12, PϽ0.01; pED 50 : fenoldopamϭ6Ϯ0.1, vehicleϭ5Ϯ0.1, nϭ12, PϽ0.05; Figure  6E ). These data indicate that D 1 and D 3 receptor have additive vasorelaxant effects.
Mechanism of D 1 and D 3 receptor-induced vasorelaxation is described herein. In norepinephrine preconstricted vessels, fenoldopam-induced and PD128907-induced vasorelaxation was increased in vessel preincubated for 30 minutes with nifedipine 25 (10 Ϫ6 M), indicating that the decreased vasorelaxant effects of fenoldopam and PD128907 in norepinephrine-preconstricted vessels may be related to a norepinephrine-induced increase in intracellular calcium ( Figure 6F and G). The vasodilatory effect of PD128907 was abrogated by apamin and charybdotoxin, indicating involvement of smallconductance and/or large-conductance calcium-activated potassium channels ( Figure 6G ). 
Discussion
The effect of D 3 receptors on arterial vascular tone is not well understood. Quinpirole, a D 3 receptor agonist with a 35-fold selectivity over the D 2 receptor, has no vascular relaxant effect on mesenteric arteries. 28 Another D 3 receptor agonist, pramipexole, with a 60 selectivity over the D 2 receptor, 20, 21 decreases vascular resistance, although part of the effect could be accounted for by an interaction with the D 1 receptor. 29 In anesthetized rats, the systemic infusion of 7-OH-DPAT, a D 3 receptor agonist with a 50-fold selectivity over the D 2 receptor, 20, 21 decreases renal blood flow by postglomerular constriction, resulting in an increase in glomerular filtration rate. 4 In conscious dogs, the intrarenal arterial infusion of quinpirole also decreases renal blood flow, but glomerular filtration rate is decreased as well. 30, 31 The reason for these apparent discrepancies is not clear. However, the effect of D 2 -like receptors on vascular tone may vary depending on the resisting tone and the arterial segment being studied 3 For example, D 1 receptor agonist increases the vascular tone of the rat tail artery. 32 In other vessels, including the renal artery, D 1 receptors are vasodilatory. 5, 6 Prejunctional D 2 -like receptors are vasodilatory whereas postjunctional D 2 -like receptors can induce vasoconstriction when resting vascular tone is low or vasodilation when resting vascular tone is high. 3 Our studies show that in the maximally vasorelaxed mesenteric artery, 2 different D 3 receptor agonists, PD128907, with a 120-fold selectivity over the D 2 receptor, 20,21 and 7-OH-DPAT, 20, 22 have no effect on vascular contractility. However, when the mesenteric rings are preconstricted, the PD128907, 7-OH-DPAT, and fenoldopam, by themselves, cause vasorelaxation. As compared with vessels preconstricted with norepinephrine, the D 1 and D 3 vasorelaxation is greater in vessels preconstricted with potassium chloride. The ability of norepinephrine to impair the vasodilatory effects of dopamine has been reported. 33 The decreased vasodilator effect of D 1 agonists in vessels preconstricted with norepinephrine may be caused by an increase of intracellular calcium by activation of ␣ 1 -adrenergic receptors. 34, 35 Our studies show that the vasorelaxant effects of fenoldopam (D 1 receptor agonist) and PD128907 (D 3 receptor agonist) are enhanced by calcium channel blockade with nifedipine. The vasodilatory effect of D 3 receptors may also involve potassium channels (small-conductance and/or large-conductance calcium activated potassium). 36, 37 Additionally, norepinephrine can also compete with the agonists for dopamine receptor occupancy. 38, 39 The vasorelaxant effect of dopamine in the rabbit pulmonary artery has been reported to be endothelium-dependent and endothelium-independent. 40 However, in our studies, despite the presence of D 3 receptors in the intima, the vasodilatory effects of the D 1 and D 3 receptor agonists are endothelium independent. The function of the D 3 receptor in endothelial cells is not clear, but D 3 receptors have cellprotective properties. 41 In human brain endothelial cells, 42 the D 3 agonist, PD128907, inhibits superoxide production, determined by cytochrome C reduction test, 43 an effect that is blocked by a D 3 antagonist, U99194A, which by itself does not have any effect (Z. Yang, C. Zeng, K.S. Kim, P.A. Jose, unpublished data, 2003) .
The simultaneous stimulation of D 1 and D 3 receptors causes a vasorelaxation that is additive rather than synergistic. This may indicate that D 1 and D 3 receptors induce vasorelaxation by different mechanisms. Our studies also indicate that the vasorelaxation of the mesenteric artery is probably caused by activation of postjunctional rather than prejunctional dopamine receptors, because neither D 1 receptor nor D 3 receptor is expressed in the tunica adventitia, where the nerve supply terminates. The reason for the inability of others to demonstrate D 3 receptors in vascular smooth muscles is not clear. 44 We find that D 1 and D 3 receptors coimmunoprecipitate, and that coimmunoprecipitation is increased by D 1 receptor stimulation. There are 2 possible explanations for this observation: increased D 1 and D 3 receptor expression, per se, or an increased physical interaction between D 1 and D 3 receptors. This interaction occurs only after several hours of treatment and may explain the absence of synergism in the acute studies in mesenteric vessels. Further studies are needed to determine whether the increased interaction between these 2 receptors is a direct or an indirect mechanism. However, homooligomerization or hetero-oligomerization of several G protein-coupled receptors have been reported. 45, 46 In summary, we have demonstrated that the D 1 receptor regulates the D 3 receptor by physical interaction and receptor expression. 
Perspectives
The vasodilator effect of dopamine via D 1 -like receptors is mediated mainly by cAMP/protein kinase A. 47, 48 It seems paradoxical that the D 3 receptor dilates the mesenteric artery because D 2 -like receptors decrease while D 1 -like receptors increase cAMP production. 1-3 D 3 receptors linkage to adenylyl cyclase inhibition is weak, unless adenylyl cyclase V is present. 49 Adenylyl cyclase isoform V has been shown in rat pulmonary arterial smooth muscles but not in aortic smooth muscles. 50 Therefore, it is likely that the D 3 receptor-mediated vasorelaxation in vascular smooth muscle cells is caused by its ability to stimulate K ϩ channels. 36 Under these conditions, the vasorelaxant effects of D 1 -like receptors caused by cAMP/PKA may be additive to the vasorelaxant effect of D 3 receptors caused by stimulation of K ϩ channels. 36, 37 
